ArticleThe American journal of case reports2026
Use of Apixaban for Venous Thromboembolism Prophylaxis in an Older Hemodialysis Patient After Total Knee Replacement: A Case Report.
Article in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Total knee arthroplasty (TKA) is associated with a significant risk of venous thromboembolism (VTE), making postoperative thromboprophylaxis essential. In patients with end-stage renal disease (ESRD) who are on hemodialysis, the choice of anticoagulant is complicated by altered drug metabolism. Although oral vitamin K antagonists (eg, warfarin) and unfractionated heparin are commonly used, there are some challenges that minimize their utilization. Direct oral anticoagulants such as apixaban can overcome these challenges, and pharmacokinetic data support their use in ESRD, but clinical evidence supporting the safety and efficacy of apixaban is limited. CASE REPORT We describe the case of a 78-year-old woman with ESRD on regular hemodialysis who underwent elective right TKA. Her postoperative course was notable only for a hemoglobin drop consistent with expected surgical blood loss, and she remained stable with no signs of bleeding or infection. Initial prophylaxis was provided with unfractionated heparin during her hospital stay. Considering her advanced age, need for hemodialysis at another center, and the logistical challenges of warfarin monitoring, apixaban 2.5 mg twice daily was selected as an off-label discharge option for VTE prophylaxis. The patient tolerated apixaban well, with no reported bleeding or thromboembolic complications during follow-up or dialysis sessions. CONCLUSIONS Apixaban appears to be a safe alternative for VTE prophylaxis after TKA in selected dialysis patients; however, its use remains off-label. More robust data are needed to guide clinical decision-making.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.